Introduction: Doxorubicin (DXR) is one of the most effective and widely used anthracycline antibiotics. However, its clinical application is hampered by toxic effects in many organs. Nephrotoxicity is one of the major side effects of anthracycline antibiotics. This study was designed to investigate the possible protective effects of aliskiren (a direct renin inhibitor) in DXR-induced nephrotoxicity in rats. Materials and methods: Wistar albino rats were intraperitoneally (ip) injected with DXR and renin activity, albumin, total protein, urea, creatinine levels in plasma and ultrastructural changes in podocytes were assessed. Results: Rats subjected to DXR administration had significant (p<0.01) increases in systolic blood pressure, plasma renin activity, plasma concentration of urea, creatinine and tissue malondialdehyde and significant (p<0.01) reductions in plasma concentrations of albumin, total protein and antioxidant defense (reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT)) in renal tissues. Furthermore, DXR-induced nephrotoxicity has also been characterized by broadening of podocyte foot processes, enlargement of glomerular basement membrane width and reduction in slit pore diameter. The above effects of DXR were significantly (p<0.01) prevented by aliskiren treatment. Conclusions: These findings revealed that the blockade of renin activity by aliskiren is a promising approach in the treatment of DXR-induced nephrotoxicity.
Introduction
Doxorubicin (DXR), an anthracycline antibiotic and is used for the treatment of a variety of neoplastic conditions including leukemias, lymphomas and solid tumors. 1 However, the optimal clinical use of DXR has been curtailed by a number of side-effects; the most important beingcardiotoxicity, and nephrotoxicity. 2,3 DXR-induced nephrotic syndrome is characterized by proteinuria and hypoalbuminemia. 4, 5 Although the exact mechanism of DXR-induced nephrotoxicity remains unknown, it is believed that the toxicity may be mediated through the generation of reactive oxygen species, 6 protein oxidation, 7 lipid peroxidation, 6, 8 and overactivity of renin that produces angiotensin II. 9 Angiotensin II, the principal effector of the renin-angiotensin system (RAS), has been reported to have a crucial role in the pathogenesis of several cardiovascular and renal injuries. 10, 11 A few studies have suggested that angiotensin-converting enzyme inhibitors (ACEIs) 12, 13 and angiotensin receptor blockers (ARBs) 9, 14 may exert a protective role towards DXR-induced nephrotoxicity. There is evidence for the role of the RAS in DXR-induced nephrotoxicity. However, ACE inhibitors 15 and ARBs 9,14 benefit DXR-induced nephrotoxicity to some extent only. This may be due to the fact that ACE inhibitors and ARBs increase renin secretion and, thereby, increase the plasma renin activity (PRA) level. This is due to the interruption of the negative feedback mechanism that regulates renin secretion in accordance with angiotensin II concentration. 16, 17 However, a direct renin inhibitor (aliskiren (ALK)), reduces PRA by blocking renin catalytic activity. 16, 17 This distinctive property of ALK led to the hypothesis that the inhibition of renin at the very first step in the RAS cascade may protect the kidney from DXR toxicity.
ALK is the first FDA-approved, orally active, direct inhibitor of renin for hypertension. This novel drug has some advantages over existing RAS blockers such as: it does not have angiotensin-converting enzyme (ACE)escape like activity, 17 it prevents the formation of both angiotensin I and angiotensin II and it produces an effective blockade of RAS without the compensatory increase in PRA. 18 More recently, ALK was shown to protect DXR cardiotoxicity in rats. 19 However, the protective effect of ALK against DXR nephrotoxicity has not been addressed to date. Therefore, the present study was designed to assess the protective potential of ALK in a chronic set up of DXR nephrotoxicity in Wistar albino rats and to compare the effect of ALK in respect of telmisartan (TEL) with a focus on renin activity and ultrastructural changes.
Materials and methods

Experimental animals
The study protocol (Protocol No. 574/2010) was approved by the Institutional Animal Ethics Committee (IAEC) of Hamdard University, New Delhi, India. Albino rats of the Wistar strain, with a body weight 160-200 g, were procured from the Central Animal House Facility, Hamdard University, New Delhi and acclimatized under standard laboratory conditions at 20-25°C. The animals were kept in propylene cages under controlled conditions of illumination and had free access to commercial pellet diet and water ad libitum.
Drugs and chemicals
DXR (Dabur India Ltd, Sahibabad, Uttra Pradesh, India), ALK (Novartis Pharmaceutical, Basel, Switzerland) and TEL (Glenmark Pharmaceutical Ltd, Kisanpura, Himachal Pradesh, India) were gratefully received for the study. Purchases were made of the angiotensin I ELISA assay kit from Phoenix Pharmaceuticals, Inc. (USA), albumin, total protein assay kits from Span Diagnostics Ltd (India), creatinine and blood urea nitrogen assay kits from Reckon Diagnostic Ltd (India). All of the other chemicals used were of analytical grade. High performance liquid chromatography (HPLC) grade water was used for all biochemical assays.
Experimental protocol
After acclimatization, rats were allocated into seven groups consisting of eight animals each. Group I served as vehicle control and received physiological saline (1 mL/kg/day, p.o.) for 42 days. (p.o. stands for per oral) Group II served as the pathogenic control and received 16 equal cumulative doses of DXR (1.25 mg/kg, ip) every alternative day, starting from the tenth day of the treatment. Groups III, IV, V and VI received ALK 30 mg/kg/day, ALK 50 mg/kg/ day, ALK 100 mg/kg/day and TEL 10 mg/kg/day, p.o. respectively for 42 days along with 16 equal cumulative doses of DXR (1.25 mg/kg, ip), the same as in group II. Group VII served as per se and received ALK alone (100 mg/kg/day, p.o.) for 42 days (per se means by itself; in this group ALK is showing effects by itself only). Blood samples were withdrawn from the tail vein on the 42 nd day of treatment for estimation of albumin, total protein, renin activity, blood urea nitrogen (BUN) and creatinine in plasma. The animals were sacrificed and kidney tissues were collected for biochemical and ultrastructural evaluation. Oxidative stress biomarkers (malondialdehyde (MDA), catalase (CAT), superoxide dismutase (SOD), and reduced glutathione (GSH)) were estimated in kidney tissues. A small piece of kidney tissue 1-2 mm thickness was preserved in phosphate buffer (strength 100 mM, pH 7.4) for ultrastructural studies.
Blood pressure
Systolic blood pressure (SBP) was measured in triplicate using the tail-cuff method (Biopac Non-Invasive Blood Pressure Recording Instrument, USA) before treatment and after the last dose of the treatment. All of the rats were initially trained in the restrainer for a period of 15 min every day at least 10-15 days prior to the day of measurement of SBP.
PRA
Renin activity was determined by detection of angiotensin I level in the plasma. 20 The microtiter plate provided in the kit was pre-coated with an antibody specific to angiotensin I. To the microtiter plate, were added 50 μL samples, 25 μL primary antibody, 25 μL biotinylated peptide, 100 μL of SA-HRP (streptavidin-horseradish peroxidase) and 100 μL of TMB (3,3',5,5' tetramethylbenzidine) substrate solution to each well and these were then incubated. Only those wells that contained angiotensin I, biotin-conjugated antibody and enzyme-conjugated avidin exhibited a change in color. The intensity of colorimetric signal, determined by spectrophotometry, is directly proportional to the amount of angiotensin I. The concentration of angiotensin I was calculated by using a standard curve.
Biochemical estimation in plasma
Albumin, 21 total protein, 22 creatinine 23 and urea 24 were estimated in plasma samples by enzymatic kits using a UV-visible spectrophotometer (Shimadzu UV-1601, Japan) according to reported procedures.
Tissue MDA and antioxidant activities
Measurement of renal MDA content was carried out by the method of Ohkawa et al. 25 Antioxidant enzymes, namely GSH, SOD and CAT, were determined in renal tissue according to the standard protocols. GSH was estimated by the method of Sedlack and Lindsay. 26 The activity of SOD was measured according to the method of Marklund and Marklund 27 and CAT was measured by the method of Clairbone. 28 The protein content was determined by the method of Lowry et al. 29 using bovine serum albumin as a standard.
Podocyte transmission electron microscopy (TEM)
Kidney tissue was fixed in modified Karnovasky's fluid, buffered with 0.1 M sodium phosphate buffers at pH 7.4. Fixation was done for 8-12 hours at 4°C. Subsequent to this the tissues were washed with 0.1 M sodium phosphate buffer. After several washes, specimens were desiccated in graded acetone solutions and rooted in CY212 araldite. Ultra-thin sections of 60-80 nm thickness were incised using an ultracut E ultramicrotome and the sections were stained in alcoholic uranyl acetate (10 min) and lead citrate (10 min) before examining the samples in a transmission electron microscope (FEI-Margagni operated 268, Netherlands) at 60-80 kV. 30 Rat podocytes were evaluated at x5000 magnification. TEM images were analyzed using Image J (public domain, National Institutes of Health (NIH), and analysis was adapted from previous work. 31, 32 Images were used to measure the slit pore diameter, basement membrane thickness and foot process base width.
Statistical analysis
The results were analyzed by analysis of variance (ANOVA) followed by Dunnett's t test to identify significance among groups. Statistical analysis were performed using GraphPad InStat 3 (San Diego, California, USA). Data are expressed as mean±standard error of mean (SEM). The value p<0.05 was considered as statistically significant.
Results
Blood pressure
SBP was higher in the DXR control rats (167±5.69 mm Hg) than in the vehicle control group (129±3.97 mm Hg) treated rats ( Figure 1 ) but was significantly lower in the ALK 100 + DXR treated group (133±3.32 mm Hg) and TEL 10 treated group (144.89±3.56 mm Hg) as compared to the DXR control group (p<0.01).
Kidney to body weight ratio
Treatment of rats with 16 equal cumulative doses of DXR (1.25 mg/kg, ip) caused a significant (p<0.01) decrease in kidney to body weight ratio as compared to vehicle control rats. However, pretreatment with ALK 100 and TEL 10 caused significant (p<0.01) amelioration in kidney to body weight ratio change as compared to DXR control treated rats ( Figure 2 ).
PRA
As shown in Figure 3 , significantly (p<0.01) increased PRA was found in DXR control treated rats as compared to vehicle control rats. However, pretreatment of rats with ALK 50 and ALK 100 resulted in a significant (p<0.01) reduction in PRA compared to the DXR control group. Although, PRA was found to be supplementary increased in TEL + DXR treated rats as compared to DXR control treated rats. This means there was an additional supplementary increase of PRA by TEL in DXR treated rats.
Albumin, total protein, creatinine and urea in plasma
A decreased concentration of plasma total proteins, albumin and increased concentration of creatinine and urea were found in the DXR control rats compared to the vehicle control rats. Pretreatment with ALK 50, ALK 100 and TEL 10 significantly restored the DXR-induced decrease in plasma proteins and increase in plasma urea and creatinine levels ( Table 1) .
Lipid peroxidation and antioxidant enzymes in renal tissues
In the DXR control rats, there was a significant increase in renal tissue MDA level compared with the vehicle control rats. Pretreatment with ALK 50, ALK 100 and TEL 10 significantly attenuated the DXR-induced increase in kidney tissue MDA ( Table 2 ). The activities of SOD, CAT and GSH in kidney tissue were determined in all the groups and the results are shown in Table 2 . In DXR-treated rats, the activities of SOD, CAT and GSH were significantly (p<0.01) lower as compared with the vehicle control group. Pretreatment with ALK 100 and TEL 10 significantly prevented the DXR-induced decrease in SOD, CAT and GSH. Figure 4 demonstrates podocytes and filtration barrier changes under TEM, magnification x5000. TEM images were used to evaluate three criteria for filtration barrier integrity: (a) basement membrane width (nm), (b) slit pore diameter (nm) and (c) podocyte foot process base width (nm). Significant changes in all three structures were observed when comparing the glomeruli of the DXR control rats with the vehicle control rats, and these changes were attenuated by pretreatment with ALK (100 mg/kg/ day) in the DXR control treated rats ( Figure 5 ). Basement membrane width was significantly greater for the DXR group (115±6 nm) than for the control group (82±3 nm) glomeruli (p<0.01). This increase was eliminated by pretreatment with ALK (100 mg/kg/day) (84±3 nm) ( Figure 5(A) ).
Ultrastructural analysis
Slit pore diameter was less in DXR (28±4 nm) glomeruli than in control (45±2 nm, p<0.01) ( Figure 5(B) ). Slit pore diameter also improved in ALK 100 + DXR group (42±5 nm) compared with DXR group (p<0.01). Foot process base width in DXR group (273±17 nm) was greater than in the control group (181±7 nm, p<0.01), while lower values were observed in DXR control group (200±8 nm, p<0.01) ( Figure 5(C) ). The lower dose of ALK (30 mg/kg/day) and TEL 10 pretreatment did not protect the podocytes from DXR-induced nephropathy. We also observed that there were non-significant (p>0.05) changes in ALK per se (100 mg/kg/day) treated rats as compared to the vehicle control group.
Discussion
Glomerular podocytopathy is one of the most common factors of proteinuric nephrotic syndrome that progresses to end-stage kidney failure. 33 To elucidate pathogenic mechanisms of DXR-induced nephrotoxicity, several experimental models are used. [34] [35] [36] In this study, rats were treated with 16 equal cumulative doses of DXR (1.25 mg/kg, ip) because this model showed the most important feature of glomerular podocytopathy which is characterized by the broadening of foot process base width, thickening of glomerular basement membrane (GBM) and reduction in slit pore diameter. The pathogenesis of DXR nephrosis has not yet been fully understood but the present study provides a good insight into this pathology and clearly indicates the involvement of blood pressure, PRA, plasma protein and oxidative stress. In our investigation, we focused on studying the changes in SBP, PRA, serum protein, oxidative stress markers and the ultrastructure of podocytes. An overactivity of plasma renin leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension and loss of kidney function. 37 Therefore, renin inhibitors can play an important role in the treatment of renal failure by checking the secretion of aldosterone from renal cortex in response to angiotensin II. In our investigation, for the first time, we report that DXR therapy resulted in an increase in PRA in pathogenic control rats as compared to vehicle control rats. ALK prevented the increase in PRA in this study and showed encouraging potential in use for its nephro-protective activity. However, in the case of TEL, increased PRA was observed as compared to DXR control treated rats. This is due to inhibition of the negative feedback mechanism that regulates renin secretion in accordance with the angiotensin II activity, as reported by earlier studies also. 16, 17 ALK was found to have inhibitory effect on PRA and this makes it better than TEL.
DXR administration also caused a decrease in body to kidney weight ratio which supports the results of previous studies. 38 This could be the result of immediate deleterious action on the intestinal mucus membrane which might have reduced food intake and decreased secretion of intestinal hormones. 39 In this study, DXR treated rats showed low plasma albumin levels (hypoalbuminemia), which is a characteristic feature of the nephrotic syndrome. 36 The result of this study also corroborates with previous studies reporting hypoalbuminemia in DXR treatment rats. 15, 35, 40 Pretreatment with ALK 100 and TEL 10 significantly reduced DXRinduced hypoalbuminemia. Therefore, it is proposed that ALK and TEL have anti-hypoalbuminemic activity. The concentration of urea and creatinine in plasma depend on the glomerular filtration rate (GFR). Renal dysfunction reduces capability to filter urea and creatinine, and the plasma creatinine and urea rises. If the plasma creatinine and urea levels double, the GFR is considered to have been halved. 8, 9 In this study, DXR-induced nephropathy was manifested by elevation in the plasma levels of BUN and creatinine. These results are in agreement with previous reports. 9, 41 However, pretreatment with ALK 100 and TEL 10 caused a significant reduction in creatinine and BUN levels which may be due to improvement in glomerular filteration damage induced by DXR.
A role of oxygen free radical formation in DXRmediated nephrotoxicity has been suggested in experimental animals. 8, 9, 15 The findings of the present study show that DXR administration decreased the GSH, SOD and GSH content of rat kidney and increased the MDA level which is consistent with the previous reports. 8, 9, 10 These findings suggest that enhanced reactive oxygen species (ROS) could be one of the mechanisms through which DXR induces nephrotoxicity. Pretreatment with ALK 100 and TEL 10 attenuated the DXR-induced rise in MDA followed by improvement in GSH, CAT and SOD levels which reflects the possible antioxidant effect of ALK and TEL in DXRinduced nephrotoxicity. In the case of antioxidant activity, TEL was found to have better protective effects than treatments with ALK 50 and ALK 100. This could be due to the fact that TEL is a partial agonist of PPARγ that might have enhanced the antioxidant properties of TEL.
The glomerular epithelial cells (podocytes) are the most differentiated cell type within the glomerular complex. 42 These are an integral component of the GBM and slit pore diaphragm, the most complex layer of the glomerular filtration barrier. 42 The main function of the slit diaphragm is to form a size-selective barrier for proteins. In DXR control treated rats, the podocyte slit pore diameter was decreased by 38% and up to half of the slits were as tight. Thus, the filtration surface area between podocytes was dramatically reduced, followed by broadening of the base of podocytes and disruption of the filtration slit structure. All of these changes were observed in the DXR control treated rats and have been associated with increases in PRA and oxidative stress in renal tissue. DXR-induced damage in filtration barrier was not improved by TEL pretreatment, as evidenced by the elongation of podocyte foot process and narrowing of slit pore diameter, and this could be due to a supplementary increase in PRA. However, increased PRA, oxidative stress and loss of glomerular filtration integrity were prevented by pretreatment with ALK 100 in the DXR treated rats. Therefore, the result of this study shows that ALK has nephroprotective effects.
In conclusion, this investigation demonstrates that podocyte injury is associated with increased PRA, lipid peroxidation, decreased antioxidant defence activity and hypoalbuminemia. In vivo treatment with a renin inhibitor significantly reduced oxidative stress and glomerular filtration injury in association with improvements in hypoalbuminemia, blood pressure and PRA. These results add further credibility to the view that overactivity of renin may be a common pathophysiological instigator of all of these abnormalities. These results also suggest that blockade of renin activity maintains glomerular filtration integrity by changing the RAS balance. Further studies are needed to validate this conclusion and find out the association between DXR-induced nephrotoxicity and RAS.
